XML 73 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Note 9 - Investment in Conduit Pharmaceuticals (Details Textual)
 1 Months Ended 3 Months Ended 6 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2024
USD ($)
shares
Apr. 22, 2024
USD ($)
$ / shares
shares
Sep. 22, 2023
USD ($)
shares
Jan. 26, 2023
shares
Feb. 07, 2022
USD ($)
$ / shares
shares
Jan. 07, 2022
USD ($)
shares
Jul. 12, 2021
shares
Oct. 31, 2024
USD ($)
shares
Feb. 28, 2023
USD ($)
Dec. 31, 2023
USD ($)
Jun. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Dec. 31, 2024
USD ($)
shares
Dec. 31, 2023
USD ($)
shares
Jan. 01, 2025
shares
Sep. 30, 2024
Sep. 21, 2023
May 11, 2023
USD ($)
Mar. 01, 2023
shares
Deconsolidation, Gain (Loss), Amount                         $ 0 $ 40,321,483          
Equity Securities, FV-NI $ 206,177                 $ 18,318,521     206,177 18,318,521          
Marketable Security, Gain (Loss)                         (17,925,723) (23,359,774)          
Reverse Stock Split [Member]                                      
Stockholders' Equity Note, Stock Split, Conversion Ratio 100                                    
Special Purpose Acquisition Company (SPAC) [Member]                                      
Financing Receivable, before Allowance for Credit Loss     $ 1,000,000                                
Former CFO [Member] | CDT Common Stock [Member]                                      
Investment Owned, Shares Transferred as Payment of Accrued Bonus (in shares) | shares               1,045,805                      
Investment Owned, Shares Transferred, Price Per Share               0.1087%                      
Investment Owned, Shares Transferred as Payment of Accrued Bonus, Value               $ 113,679                      
Murphy Canyon Acquisition Sponsor, LLC [Member]                                      
Intangible Assets, Net (Excluding Goodwill)                                   $ 5,000,001  
Deconsolidation, Gain (Loss), Amount     6,200,000             40,300,000       40,300,000          
Deconsolidation, Revaluation of Retained Investment, Gain (Loss), Amount     $ 34,100,000                     $ 34,100,000          
Conduit Pharmaceuticals Inc [Member]                                      
Stock Issued During Period, Shares, New Issues (in shares) | shares     754,000                                
Stock Issued During Period, Shares, Acquisitions (in shares) | shares     65,000,000                                
Conduit Pharmaceuticals Inc [Member] | Director [Member]                                      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares     45,000                                
Stock Issued During Period, Shares, Issued for Services (in shares) | shares     45,000                                
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                                      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares   540,000 754,000                                
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares   $ 3.12                                  
Warrants and Rights Outstanding, Term (Year)   2 years                                  
Warrant or Right, Exercisable Period (Year)   1 year                                  
Warrants and Rights Outstanding $ 0 $ 891,000                     0            
Conduit Pharmaceuticals Inc [Member] | Conversion of Class B to Class A Common Stock [Member]                                      
Stock Issued During Period, Shares, Conversion of Convertible Securities (in shares) | shares     3,306,250                                
Common Class A [Member]                                      
Stock Redeemed or Called During Period, Shares (in shares) | shares                           11,037,272          
Stock Subject to Possible Redemption, Shares (in shares) | shares                                     2,187,728
Stock Issued During Period, Shares, New Issues (in shares) | shares             1,000,000                        
Common Class A [Member] | Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                                      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares     754,000                                
Trust for the SPAC Class A Common Stockholders [Member]                                      
Cash Withdrawn From Trust Account                     $ 114,100,000                
Trust Account, Income Tax Withdraws                 $ 200,050                    
Trust Account, Extension Payments                 $ 155,403                    
Investments                     $ 23,300,000                
Investment Income, Net                       $ 1,200,000              
Conduit Pharmaceuticals Inc [Member]                                      
Lock-up Agreement, Shares (in shares) | shares   2,700,000                                  
Investment Owned, Balance, Shares (in shares) | shares   4,015,250                                  
Equity Securities, FV-NI 200,000                 18,300,000     200,000 $ 18,300,000          
Investment Owned, Fair Value $ 200,000                       200,000            
Marketable Security, Gain (Loss)                         $ (17,900,000) (23,400,000)          
Investment Owned, Cost                   $ 7,500,000       $ 7,500,000          
Conduit Pharmaceuticals Inc [Member] | CDT Common Stock [Member]                                      
Investment Owned, Balance, Shares (in shares) | shares 2,944,514             2,944,514         2,944,514            
Conduit Pharmaceuticals Inc [Member] | CDT Common Stock [Member] | Subsequent Event [Member]                                      
Investment Owned, Balance, Shares (in shares) | shares                             29,445        
Conduit Pharmaceuticals Inc [Member] | CDTTW Warrants [Member]                                      
Investment Owned, Balance, Shares (in shares) | shares 709,000             709,000         709,000            
Conduit Pharmaceuticals Inc [Member] | Private Warrants [Member]                                      
Investment Owned, Balance, Shares (in shares) | shares               540,000                      
The “Merger Consideration” [Member]                                      
Stock Redeemed or Called During Period, Shares (in shares) | shares       11,037,272                              
Special Purpose Acquisition Company (SPAC) [Member]                                      
Subsidiary, Ownership Percentage, Parent                                 65.00%    
Conduit Pharmaceuticals Inc [Member]                                      
Investment Owned, Net Assets, Percentage     6.50%                         1.00%      
SPAC, Initial Public Offering [Member] | Murphy Canyon Acquisition Sponsor, LLC [Member]                                      
Proceeds from Issuance of Common Stock         $ 132,250,000 $ 132,250,000                          
Subsidiary, Ownership Percentage, Parent           23.50%                          
Units Issued During Period, Units, New Issues (in shares) | shares         13,225,000 132,250,000                          
SPAC Units, Composition, Number of Shares Per Unit (in shares) | shares           1                          
SPAC, Placement Units, Number of Units Purchased (in shares) | shares         754,000                            
SPAC, Placement Units, Price Per Share (in dollars per share) | $ / shares         $ 10                            
SPAC, Purchase Units, Payments for the Purchase of Equity         $ 7,540,000                            
Stock Issuance Costs         7,738,161                            
Underwriting Discounts and Commission         2,645,000                            
Deferred Underwriting Fees         4,628,750                            
Other Equity Offering Costs         $ 464,411